MX384368B - Pirimidinas y sus variantes, y usos de las mismas. - Google Patents
Pirimidinas y sus variantes, y usos de las mismas.Info
- Publication number
- MX384368B MX384368B MX2018011622A MX2018011622A MX384368B MX 384368 B MX384368 B MX 384368B MX 2018011622 A MX2018011622 A MX 2018011622A MX 2018011622 A MX2018011622 A MX 2018011622A MX 384368 B MX384368 B MX 384368B
- Authority
- MX
- Mexico
- Prior art keywords
- present disclosure
- disclosure provides
- pyrimidines
- variants
- potential treatment
- Prior art date
Links
- 150000003230 pyrimidines Chemical class 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 102100040460 P2X purinoceptor 3 Human genes 0.000 abstract 1
- 101710189970 P2X purinoceptor 3 Proteins 0.000 abstract 1
- 102000000033 Purinergic Receptors Human genes 0.000 abstract 1
- 108010080192 Purinergic Receptors Proteins 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 210000001835 viscera Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/50—Three nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662313334P | 2016-03-25 | 2016-03-25 | |
| PCT/US2017/023126 WO2017165255A1 (en) | 2016-03-25 | 2017-03-20 | Pyrimidines and variants thereof, and uses therefor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018011622A MX2018011622A (es) | 2019-03-28 |
| MX384368B true MX384368B (es) | 2025-03-14 |
Family
ID=59900805
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018011622A MX384368B (es) | 2016-03-25 | 2017-03-20 | Pirimidinas y sus variantes, y usos de las mismas. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10662162B2 (enExample) |
| EP (1) | EP3433258B1 (enExample) |
| JP (1) | JP6902045B2 (enExample) |
| KR (1) | KR102377805B1 (enExample) |
| CN (1) | CN108779119B (enExample) |
| AU (1) | AU2017237929B2 (enExample) |
| CA (1) | CA3018180C (enExample) |
| MA (1) | MA44489A (enExample) |
| MX (1) | MX384368B (enExample) |
| RU (1) | RU2760733C2 (enExample) |
| WO (1) | WO2017165255A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10822311B2 (en) | 2016-03-14 | 2020-11-03 | Afferent Pharmaceuticals, Inc. | Pyrimidines and variants thereof, and uses therefor |
| AU2017237929B2 (en) | 2016-03-25 | 2021-04-15 | Afferent Pharmaceuticals Inc. | Pyrimidines and variants thereof, and uses therefor |
| CA3044366A1 (en) | 2016-12-19 | 2018-06-28 | Novartis Ag | New picolinic acid derivatives and their use as intermediates |
| MX381790B (es) * | 2016-12-20 | 2025-03-13 | Afferent Pharmaceuticals Inc | Sales cristalinas y polimorfos de un antagonista de p2x3. |
| CN117186068A (zh) | 2017-11-01 | 2023-12-08 | 北京泰德制药股份有限公司 | P2x3和/或p2x2/3受体拮抗剂、包含其的药物组合物及其用途 |
| CN107778255B (zh) * | 2017-11-16 | 2019-10-25 | 山东大学 | 一种二芳基嘧啶类hiv-1逆转录酶抑制剂及其制备方法和应用 |
| EP3964505B1 (en) * | 2019-04-30 | 2025-10-15 | Beijing Tide Pharmaceutical Co., Ltd. | Solid form of diaminopyrimidine compound or hydrate thereof, preparation method therefor, and application thereof |
| SG11202111960PA (en) * | 2019-04-30 | 2021-12-30 | Beijing Tide Pharmaceutical Co Ltd | Method for treating endometriosis-associated pain by using diaminopyrimidine compound |
| EP3960179B1 (en) * | 2019-04-30 | 2026-03-18 | Beijing Tide Pharmaceutical Co., Ltd. | Method for treating cough by using diaminopyrimidine compound |
| US12595261B2 (en) | 2019-06-06 | 2026-04-07 | Beijing Tide Pharmaceutical Co., Ltd. | P2X3 and/or P2X2/3 receptor antagonist, pharmaceutical composition containing same, and use thereof |
| CN120058573B (zh) * | 2025-04-29 | 2025-12-23 | 潍坊学院 | 一种1-三溴甲基磺酰基萘及其衍生物的合成方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2953567A (en) * | 1956-11-23 | 1960-09-20 | Burroughs Wellcome Co | 5-phenylmercaptopyrimidines and method |
| EP1165522A1 (en) * | 1999-04-06 | 2002-01-02 | Krenitsky Pharmaceuticals, Inc. | Neurotrophic thio substituted pyrimidines |
| BR0116493A (pt) * | 2000-12-21 | 2003-09-30 | Vertex Pharma | Compostos de pirazol úteis como inibidores de proteìna cinase |
| PT1725540E (pt) * | 2004-03-05 | 2012-11-29 | Hoffmann La Roche | Diaminopirimidinas como antagonistas de p2x3 e p2x2/3 |
| AU2006286576B2 (en) * | 2005-09-01 | 2012-06-14 | F. Hoffmann-La Roche Ag | Diaminopyrimidines as P2X3 and P3X2/3 modulators |
| ES2562056T3 (es) | 2005-09-01 | 2016-03-02 | F. Hoffmann-La Roche Ag | Diaminopirimidinas como moduladores P2X3 y P2X2/3 |
| ES2612890T3 (es) * | 2005-09-01 | 2017-05-19 | F. Hoffmann-La Roche Ag | Diaminopirimidinas como moduladores de P2X3 y P2X2/3 |
| SI1924264T1 (sl) * | 2005-09-01 | 2013-12-31 | F. Hoffmann-La Roche Ag | Diaminopirimidini kot modulatorji p2x3 in p2x2/3 |
| DK2343281T3 (en) * | 2006-10-04 | 2014-03-24 | Hoffmann La Roche | Process for the Synthesis of Phenoxydiamino-Pyrimidine Derivatives |
| WO2008104472A1 (en) * | 2007-02-28 | 2008-09-04 | F. Hoffmann-La Roche Ag | 2, 4 -diaminopyrimidine derivatives and their use as p2x antagonists or as prodrugs thereof |
| WO2008104474A1 (en) * | 2007-02-28 | 2008-09-04 | F. Hoffmann-La Roche Ag | Diaminopyrimidines |
| JP5423679B2 (ja) * | 2007-10-31 | 2014-02-19 | 日産化学工業株式会社 | ピリダジノン化合物及びｐ２ｘ７受容体阻害剤 |
| GB2471713A (en) | 2009-07-08 | 2011-01-12 | Univ Greenwich | 1,2,4-triazine derivatives and their use as sodium channel blockers |
| TWI637949B (zh) * | 2013-06-14 | 2018-10-11 | 塩野義製藥股份有限公司 | 胺基三衍生物及含有其等之醫藥組合物 |
| PE20160431A1 (es) * | 2013-08-23 | 2016-06-02 | Afferent Pharmaceuticals Inc | Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, sub-aguda o cronica |
| US10195198B2 (en) * | 2014-07-03 | 2019-02-05 | Afferent Pharmaceuticals, Inc. | Methods and compositions for treating diseases and conditions |
| US10822311B2 (en) * | 2016-03-14 | 2020-11-03 | Afferent Pharmaceuticals, Inc. | Pyrimidines and variants thereof, and uses therefor |
| AU2017237929B2 (en) | 2016-03-25 | 2021-04-15 | Afferent Pharmaceuticals Inc. | Pyrimidines and variants thereof, and uses therefor |
-
2017
- 2017-03-20 AU AU2017237929A patent/AU2017237929B2/en active Active
- 2017-03-20 CA CA3018180A patent/CA3018180C/en active Active
- 2017-03-20 KR KR1020187029805A patent/KR102377805B1/ko active Active
- 2017-03-20 MX MX2018011622A patent/MX384368B/es unknown
- 2017-03-20 WO PCT/US2017/023126 patent/WO2017165255A1/en not_active Ceased
- 2017-03-20 MA MA044489A patent/MA44489A/fr unknown
- 2017-03-20 CN CN201780019534.0A patent/CN108779119B/zh active Active
- 2017-03-20 JP JP2018549444A patent/JP6902045B2/ja active Active
- 2017-03-20 EP EP17770880.7A patent/EP3433258B1/en active Active
- 2017-03-20 RU RU2018137032A patent/RU2760733C2/ru active
- 2017-03-20 US US16/080,840 patent/US10662162B2/en active Active
-
2020
- 2020-04-13 US US16/846,452 patent/US11230532B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20200239421A1 (en) | 2020-07-30 |
| US11230532B2 (en) | 2022-01-25 |
| EP3433258B1 (en) | 2023-07-19 |
| AU2017237929A1 (en) | 2018-09-13 |
| CA3018180A1 (en) | 2017-09-28 |
| RU2018137032A3 (enExample) | 2020-05-22 |
| RU2018137032A (ru) | 2020-04-27 |
| RU2760733C2 (ru) | 2021-11-30 |
| JP2019510025A (ja) | 2019-04-11 |
| JP6902045B2 (ja) | 2021-07-14 |
| KR20180128015A (ko) | 2018-11-30 |
| BR112018069105A2 (pt) | 2019-01-29 |
| EP3433258A4 (en) | 2019-10-30 |
| EP3433258A1 (en) | 2019-01-30 |
| CN108779119B (zh) | 2022-02-08 |
| AU2017237929B2 (en) | 2021-04-15 |
| CN108779119A (zh) | 2018-11-09 |
| KR102377805B1 (ko) | 2022-03-22 |
| WO2017165255A1 (en) | 2017-09-28 |
| CA3018180C (en) | 2024-02-20 |
| MA44489A (fr) | 2019-01-30 |
| MX2018011622A (es) | 2019-03-28 |
| US10662162B2 (en) | 2020-05-26 |
| US20190055202A1 (en) | 2019-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018011136A (es) | Pirimidinas y variantes de estas, y usos de estas. | |
| MX2018011622A (es) | Pirimidinas y sus variantes, y usos de las mismas. | |
| SV2018005775A (es) | Forma polimorfa de n-{6-(2-hidroxipropan-2-il)-2-[2-(metilsulfonil)etil]-2h-indazol-5-il}-6-(trifluorometil)piridin-2- carboxamida | |
| MX2022004101A (es) | Composiciones de oligonucleotidos y metodos de uso de las mismas. | |
| CO2019012353A2 (es) | Formulaciones de anticuerpos anti-lag3 y coformulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1 | |
| CO2019004003A2 (es) | Composiciones y anticuerpos anti-lag-3 | |
| MX2022001299A (es) | Composiciones y métodos para unir dominios extracelulares de tipo i y tipo ii como proteínas quiméricas heterólogas. | |
| MX2019014228A (es) | Compuestos de biarilo utiles para el tratamiento de enfermedades humanas en oncologia, neurologia e inmunologia. | |
| CL2018003582A1 (es) | Composiciones para modular la expresión de c9orf72 (divisional solicitud 201702567) | |
| MX2018001395A (es) | Derivados de pirazol pirimidina y sus usos. | |
| BR112019010342A2 (pt) | composições do irna de serpina1 e métodos de uso destas | |
| ECSP19015192A (es) | Composiciones y métodos de inhibir masp-3 para el tratamiento de diversas enfermedades y trastornos | |
| MX373341B (es) | INHIBIDORES DE PROTEíNA CINASA 2 ACTIVADA POR PROTEíNA CINASA ACTIVADA POR MITóGENO (MK2) Y SUS USOS. | |
| MX2017010864A (es) | Anticuerpos contra tau y sus usos. | |
| DOP2017000097A (es) | Composiciones y métodos de uso para tratar trastornos metabólicos | |
| CL2018001652A1 (es) | Composiciones y métodos para disminuir la expresión de tau | |
| CL2019003270A1 (es) | Carboxamidas de octa hidrofenantreno - bis y conjugados de proteína. | |
| CL2020002103A1 (es) | Anticuerpos anti-htra1 y metodos de uso de los mismos. (divisional solicitud 201801139) | |
| DOP2018000219A (es) | Anticuerpos anti-factor bb del complemento y usos de estos | |
| NI201600129A (es) | Inhibidores de diacilglicerol aciltransferasa 2 | |
| MX386146B (es) | Métodos para tratar esclerosis múltiple usando compuestos de pirimidina y piridina con actividad inhibidora de tirosina cinasa de bruton. | |
| CU20190101A7 (es) | Imidazopirimidinas diazabicíclicas sustituidas | |
| MX388890B (es) | Metodos para tratar cancer usando compuestos de pirimidina y piridina con actividad inhibidora de tirosina cinasa de bruton. | |
| EP3355889A4 (en) | DIAMINOPYRIMIDINE P2X3 AND P2X2 / 3 RECEPTOR MODULATORS FOR USE IN THE TREATMENT OF HUSTEN | |
| MX2021002301A (es) | Bioconjugados de anticuerpo-foliato anti-cd3 y sus usos. |